Market Place
Sourcing Support
Ankyra Doses First Visceral Tumor Patient in Phase 1 ANCHOR Trial
05 Nov 2024 //
BUSINESSWIRE
Ankyra Appoints Dr Butchko And Ms Withington To Board
23 Sep 2024 //
BUSINESSWIRE
Ankyra`s ANK-101 Phase 1 Amendment, ASCO Trial In Progress Presentation
01 Jun 2024 //
BUSINESSWIRE
Ankyra and Jenga Bio Announce Exclusive License Agreement for JEN-101
26 Mar 2024 //
BUSINESSWIRE
Ankyra Announces First Patient Dosed in Phase 1 Trial Evaluating ANK-101
05 Mar 2024 //
BUSINESSWIRE
Ankyra Announces Pre-Clinical Research Published in December JCI Insight
12 Dec 2023 //
BUSINESSWIRE
Ankyra Announces Trial Agreement with Regeneron to Evaluate ANK-101
13 Nov 2023 //
BUSINESSWIRE
Ankyra Receives FDA IND and Health Canada CTA Approval to Advance ANK-101
24 Oct 2023 //
BUSINESSWIRE
Ankyra Therapeutics Presents Phase 1 Canine Clinical Data Evaluating cANK-101
14 Oct 2023 //
BUSINESSWIRE
Ankyra Announces Clinical Trial Collaboration and Supply Agreement with Merck
04 Oct 2023 //
BUSINESSWIRE
Ankyra Therapeutics Presents Preliminary Canine Clinical Data with cANK-101
19 Apr 2023 //
BUSINESSWIRE
Ankyra Appoints Financial Executive Stephen Gorgol as CFO
21 Mar 2023 //
BUSINESSWIRE
Ankyra Therapeutics Announces Collaboration to Evaluate ANK-101 in Trials
07 Feb 2023 //
BUSINESSWIRE
Ankyra Therapeutics Presents +ve Preclinical Data Supporting of ANK-101
10 Nov 2022 //
BUSINESSWIRE
Ankyra Therapeutics Appoints Joseph J. Elassal as Chief Medical Officer
17 Oct 2022 //
BUSINESSWIRE
Ankyra Tx Announces Research Collaboration with College of Veterinary Medicine
03 Jun 2022 //
BUSINESSWIRE
Ankyra inks NCI pact to support cancer pipeline progress
19 Apr 2022 //
FIERCEBIOTECH
Ankyra Therapeutics Appoints Howard L. Kaufman, MD as President and CEO
28 Mar 2022 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.